Hearing Loss Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Hearing Loss clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 2

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Head and Neck CancerHearing Loss
National Institute on Deafness and Other Communication Disorders (NIDCD)224 enrolled5 locationsNCT04915183
Recruiting
Phase 1

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

Hearing LossMetastatic Malignant Germ Cell TumorMetastatic Malignant Nongerminomatous Germ Cell Tumor+4 more
City of Hope Medical Center44 enrolled1 locationNCT07218913
Recruiting

New Approach to Objectively Measure Social Engagement in Older Adults With Hearing Loss

Hearing Loss, Bilateral (Causes Other Than Tumors)
University of Southern California100 enrolled2 locationsNCT06781749
Recruiting
Not Applicable

HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms

Cognitive ImpairmentDementiaAlzheimer Disease+1 more
Johns Hopkins University300 enrolled1 locationNCT06930560
Recruiting

NIDCD Otolaryngology Clinical Protocol Biospecimen Bank

Head and Neck NeoplasmsHearing LossHearing Disorders+1 more
National Institute on Deafness and Other Communication Disorders (NIDCD)1,000 enrolled1 locationNCT06303180
Recruiting
Not Applicable

OTC Hearing Aid and MCI

Mild Cognitive ImpairmentHearing LossAlzheimer Disease and Related Dementias (ADRD)
Northwestern University50 enrolled3 locationsNCT06112860
Recruiting
Not Applicable

Assessing Pharmacy Technician Educational Training for the Provision of Over-the-Counter Hearing Aids in Rural Alabama and Mississippi Pharmacies

Bilateral Hearing LossHealth Services Research
University of Alabama, Tuscaloosa144 enrolled2 locationsNCT06864273
Recruiting
Not Applicable

Early Age-Related Hearing Loss Investigation (EARHLI)

Cognitive ImpairmentAlzheimer DiseaseHearing Loss
Columbia University150 enrolled1 locationNCT06174038
Recruiting
Not Applicable

Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia

Dementia of Alzheimer TypeHearing Loss, SensorineuralAmnestic Mild Cognitive Impairment
Northwestern University20 enrolled2 locationsNCT04240561
Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Multiple Endocrine Neoplasia Type 1Multiple Endocrine Neoplasia Type 2Rare Disorders+337 more
Sanford Health20,000 enrolled2 locationsNCT01793168
Recruiting
Not Applicable

Evaluation of Deep Brain Stimulation (DBS) of the Right Operculum 3 (OP3) in Permanent Non-pulsatile Disabling Tinnitus (TINNOP3-DBS)

Severe Permanent Uni or Bilateral Non-pulsatile TinnitusWithout Associated Vestibular PathologyResistant to Therapeutic Failure+1 more
University Hospital, Grenoble7 enrolled1 locationNCT04296097
Recruiting
Phase 2

ACOU085 for Hearing Loss Prevention in Testicular Cancer Patients Receiving Cisplatin

Cisplatin-induced Hearing Loss
Acousia Therapeutics GmbH40 enrolled10 locationsNCT06521190
Recruiting

The Effects on Auditory Function of RADiotherapy and Chemotherapy Treatments for Head and Neck Tumours (EARAD)

Head and Neck NeoplasmsHearing Loss
University of Manchester100 enrolled1 locationNCT03914378